Innoviva announces FDA acceptance and priority review of new drug application for sulbactam-durlobactam

30 November 2022 - Sulbactam-durlobactam is a targeted antibiotic that was specifically designed to treat serious infections caused by Acinetobacter baumannii, ...

Read more →

European Commission grants expanded marketing authorisation for Gilead’s Biktarvy for the treatment of HIV in paediatric populations

29 November 2022 - European Commission authorises a low dose tablet for HIV treatment in virologically suppressed children at least two ...

Read more →

Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis

2 November 2022 - NICE is unable to make a recommendation on slow-release potassium bicarbonate–potassium citrate (Sibnayal) for treating distal renal ...

Read more →

Oestradiol hemifumarate with norethisterone acetate and relugolix for the treatment of moderate to severe symptoms of uterine fibroids

19 October 2022 - NICE has published evidence based recommendations on the use of oestradiol hemifumarate with norethisterone acetate and ...

Read more →

Evusheld receives Health Canada approval for treatment of COVID-19

18 October 2022 - Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase 3 treatment trial. ...

Read more →

COVID-19: nirmatrelvir/ritonavir reduces the risk of a severe course in patients at risk

4 October 2022 - However, due to contra-indications and interactions, the combination of active ingredients is not suitable for all patients ...

Read more →

Newly approved ALS drug Relyvrio to face its next challenge: pricing and reimbursement

4 October 2022 - There’s a swirl of controversy surrounding last week’s regulatory approval of Relyvrio (sodium phenylbutyrate and taurursodiol), which ...

Read more →

Why non-funding of cystic fibrosis treatment is unacceptable

30 September 2022 - Edward Lee has self-funded the Trikafta drug that alleviates the symptoms of his cystic fibrosis since 2019. ...

Read more →

FDA approves new treatment option for patients with ALS

29 September 2022 - The US FDA today approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis, commonly ...

Read more →

My brother is dying while there's a drug that could stop this

26 September 2022 - PHARMAC announced on Friday last week that Trikafta, a potentially life-saving drug for those suffering with ...

Read more →

Bausch Health and Glenmark announce the approval of Ryaltris in Canada

23 September 2022 - Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) treats moderate to severe seasonal allergic rhinitis and associated ...

Read more →

Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19

20 September 2022 - Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase 3 treatment trial. ...

Read more →

Evusheld long-acting antibody combination recommended for approval in the EU for the treatment of COVID-19

16 September 2022 - Recommendation based on TACKLE Phase 3 treatment data showing reduced risk of severe COVID-19 or death. ...

Read more →

PHARMAC can't progress cystic fibrosis drug Trikafta - CF New Zealand

16 September 2022 - PHARMAC is not in a position to progress funding on the life-extending cystic fibrosis drug, Trikafta, ...

Read more →

B.C. family grateful for expanded funding to cystic fibrosis drug, but questions why it took so long

7 September 2022 - B.C. is last Canadian jurisdiction to fund Trikafta for patients with cystic fibrosis age 6 to 11. ...

Read more →